Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Exchange Rate Effect (2022 - 2025)

Historic Exchange Rate Effect for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to -$2.0 million.

  • Indivior Pharmaceuticals' Exchange Rate Effect fell 10000.0% to -$2.0 million in Q3 2025 from the same period last year, while for Dec 2024 it was $1.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.0 million for FY2023, which is 20000.0% up from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Exchange Rate Effect stood at -$2.0 million, which was down 10000.0% from $1.0 million recorded in Q4 2024.
  • Indivior Pharmaceuticals' 5-year Exchange Rate Effect high stood at $2.0 million for Q4 2023, and its period low was -$2.0 million during Q3 2025.
  • Over the past 4 years, Indivior Pharmaceuticals' median Exchange Rate Effect value was -$1.0 million (recorded in 2022), while the average stood at -$142857.1.
  • Its Exchange Rate Effect has fluctuated over the past 5 years, first soared by 10000.0% in 2023, then tumbled by 10000.0% in 2025.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' Exchange Rate Effect stood at $1.0 million in 2022, then soared by 100.0% to $2.0 million in 2023, then crashed by 50.0% to $1.0 million in 2024, then plummeted by 300.0% to -$2.0 million in 2025.
  • Its last three reported values are -$2.0 million in Q3 2025, $1.0 million for Q4 2024, and -$1.0 million during Q3 2024.